Table 2.
Univariate analysis of overall survival in AEG
| Parameters | Category | No of events (%) | Median survival time (months) | 95% confidence interval | P-value |
|---|---|---|---|---|---|
| Depth of invasion | T1+T2 | 19 (32.8) | 28 | 24.3–36.5 | 0.024 |
| T3+T4 | 33 (53.2) | 20 | 19.5–36.1 | ||
| Lymph node metastasis | Negative | 17 (36.9) | 40 | 21.0–58.6 | 0.001 |
| Positive | 35 (47.3) | 30 | 17.0–34.3 | ||
| TIMP-1 | Negative | 20 (55.6) | 29 | 25.6–40.1 | 0.040 |
| Positive | 32 (38.1) | 33 | 30.8–40.4 | ||
| MMP-9 | Negative | 36 (50.7) | 41 | 30.6–43.3 | 0.037 |
| Positive | 16 (32.7) | 22 | 13.4–31.7 | ||
| MMP-9+/TIMP-1- | Yes | 21 (65.6) | 18 | 14.2–30.5 | 0.001 |
| No | 31 (35.2) | 35 | 28.1–47.6 | ||
| Adjuvant chemotherapy | No | 15 (48.4) | 26 | 22.8–34.5 | 0.050 |
| Yes | 37 (41.5) | 31 | 29.6–40.2 |
Abbreviations: AEG, adenocarcinoma of esophagogastric junction; MMP-9, matrix metalloproteinase 9; T, tumor (TNM staging system); TIMP, tissue inhibitor of metalloproteinase.